John Goffin

John Goffin

UNVERIFIED PROFILE

Are you John Goffin?   Register this Author

Register author
John Goffin

John Goffin

Publications by authors named "John Goffin"

Are you John Goffin?   Register this Author

43Publications

1077Reads

33Profile Views

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.

Lung Cancer 2017 02 15;104:65-69. Epub 2016 Dec 15.

Ontario Clinical Oncology Group, McMaster University, 711 Concession St, Hamilton, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.12.004DOI Listing
February 2017

Lung Cancer Screening, Cancer Treatment, and Addressing the Continuum of Health Risks Caused by Tobacco.

Am Soc Clin Oncol Educ Book 2016 ;35:223-9

From the Departments of Radiation Oncology and Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC; Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_158704DOI Listing
January 2017

American Society of Clinical Oncology Policy Brief: FDA's Regulation of Electronic Nicotine Delivery Systems and Tobacco Products.

J Oncol Pract 2017 01 23;13(1):58-60. Epub 2016 Oct 23.

American Society of Clinical Oncology, Alexandria, VA; Medical University of South Carolina, Charleston, SC; McMaster University Juravinski Cancer Centre, Hamilton, Ontario, Canada; Emory University, Winship Cancer Institute, Atlanta, GA; and Moffit Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.018200DOI Listing
January 2017

Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.

Lung Cancer 2016 11 28;101:98-103. Epub 2016 Sep 28.

Department of Oncology, McMaster University, 699 Concession St., Hamilton, ON, L8V 5C2, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.09.013DOI Listing
November 2016

Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses--Reply.

JAMA Oncol 2016 Feb;2(2):278-9

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4462DOI Listing
February 2016

Perspective on the National Comprehensive Cancer Network's Clinical Practice Guidelines for Smoking Cessation.

J Oncol Pract 2016 Jan 15;12(1):55-8. Epub 2015 Sep 15.

Memorial Sloan Kettering Cancer Center, New York, NY; Juravinski Cancer Centre, McMaster University, Hamilton, Canada; American University of Beirut, Beirut, Lebanon; and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.006148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979976PMC
January 2016

Cost-effectiveness of Lung Cancer Screening in Canada.

JAMA Oncol 2015 Sep;1(6):807-13

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.2472DOI Listing
September 2015

Resource utilization and costs during the initial years of lung cancer screening with computed tomography in Canada.

J Thorac Oncol 2014 Oct;9(10):1449-58

*The Canadian Centre for Applied Research in Cancer Control, and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada; †The British Columbia Cancer Agency, Vancouver, British Columbia, Canada; ‡Brock University, St. Catherines, Ontario, Canada; §Cancer Care Ontario and the Juravinski Cancer Centre, Hamilton, Ontario, Canada; ‖University Health Network and Princess Margaret Cancer Centre, Toronto, Ontario, Canada; ¶The Canadian Centre for Applied Research in Cancer Control, the British Columbia Cancer Agency and School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada; #The University of British Columbia School of Population and Public Health, Vancouver, British Columbia, Canada; **Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada; ††The British Columbia Cancer Agency and The Canadian Centre for Applied Research in Cancer Control and the University of British Columbia, Vancouver, British Columbia, Canada; ‡‡Beatrice Hunter Cancer Research Institute and Dalhousie University, Halifax, Nova Scotia, Canada; §§The Vancouver General Hospital, Vancouver, British Columbia, Canada; ‖‖Fionna Stanley Hospital and Sir Charles Gairdner Hospital, Perth, Western Australia; ¶¶Université Laval, Québec, Canada; ##Vancouver General Hospital, The University of British Columbia, Vancouver, British Columbia, Canada; ***The Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada; †††Princess Margaret Cancer Centre, Toronto, Ontario, Canada; ‡‡‡University of Calgary, Foothills Medical Centre, Calgary, Alberta, Canada; §§§Foothills Medical Centre, Calgary, Alberta, Canada; ‖‖‖Memorial University, St. Johns, Newfoundland, Canada; ¶¶¶The Ottawa Hospital, Ottawa, Ontario, Canada; ###Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; ****The Vancouver General Hospital and The University of British Columbia, Vancouver, British

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165479PMC
October 2014

Epidermal growth factor receptor: pathway, therapies, and pipeline.

Clin Ther 2013 Sep;35(9):1282-303

Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2013.08.007DOI Listing
September 2013

Canadian Cancer Risk Management Model: evaluation of cancer control.

Int J Technol Assess Health Care 2013 Apr 20;29(2):131-9. Epub 2013 Mar 20.

Juravinski Cancer Centre at Hamilton Health Sciences and Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S0266462313000044DOI Listing
April 2013

Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis.

Palliat Med 2012 Sep 15;26(6):797-803. Epub 2011 Aug 15.

Queen's University, Faculty of Medicine, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269216311415454DOI Listing
September 2012

A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.

Invest New Drugs 2012 Jun 28;30(3):1203-7. Epub 2011 Apr 28.

University Health Network-Princess Margaret Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-011-9673-xDOI Listing
June 2012

Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.

BMC Med Res Methodol 2011 Dec 12;11:164. Epub 2011 Dec 12.

McMaster University, Juravinski Cancer Centre, Hamilton, Ontario L8V 5C2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2288-11-164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259049PMC
December 2011

Early stopping rules in oncology: considerations for clinicians.

Eur J Cancer 2011 Nov 16;47(16):2381-6. Epub 2011 Jun 16.

Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.05.019DOI Listing
November 2011

A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials.

BMC Med Res Methodol 2011 Jun 21;11:95. Epub 2011 Jun 21.

McMaster University, Juravinski Cancer Centre, 699 Concession St,, Hamilton, Ontario, L8V 5C2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2288-11-95DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138426PMC
June 2011

First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review.

J Thorac Oncol 2010 Feb;5(2):260-74

Juravinski Cancer Centre at Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181c6f035DOI Listing
February 2010

Phase II stopping rules that employ response rates and early progression.

J Clin Oncol 2008 Aug;26(22):3715-20

Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.1044DOI Listing
August 2008

Overstated conclusions of a pooled analysis of bevacizumab in colon cancer.

J Clin Oncol 2006 Jan;24(3):528-9; author reply 529-30

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.04.3570DOI Listing
January 2006

Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.

Clin Cancer Res 2005 Aug;11(16):5928-34

National Cancer Institute of Canada Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0130DOI Listing
August 2005

DEALE-ing with lung cancer and heart failure.

Med Decis Making 2005 Jan-Feb;25(1):82-94

Department of Medicine, Division of Clinical Desicion Making, Tufts-New England Medical Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0272989X05274523DOI Listing
May 2005

Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer.

Am J Clin Oncol 2004 Apr;27(2):172-7

McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.coc.0000054890.69365.3eDOI Listing
April 2004

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.

Cancer Res 2004 Feb;64(3):830-5

Program in Cancer Genetics and Department of Oncology, Research Institute of the McGill University Health Centre, and Cancer Prevention Centre, Sir M. B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.can-03-2970DOI Listing
February 2004

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

J Natl Cancer Inst 2003 Oct;95(19):1482-5

Program in Cancer Genetics, Department of Oncology and Human Genetics, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djg050DOI Listing
October 2003

Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.

Cancer Res 2002 Dec;62(23):6808-11

Department of Pathology, The Gade Institute, University of Bergen, Bergen 5021, Norway.

View Article

Download full-text PDF

Source
December 2002